Abstract Number: 0573 • ACR Convergence 2020
Effects of Successive Switches of Two Different Biosimilars of Etanercept on Outcomes in Inflammatory Rheumatic Diseases in Daily Practice
Background/Purpose: A single switch from an originator to a biosimilar product has been shown to be safe and effective in the treatment of rheumatic musculoskeletal…Abstract Number: 0804 • ACR Convergence 2020
Factors That Influence Biological Survival in Rheumatoid Arthritis: Results of a Real-world Cohort from the Netherlands
Background/Purpose: Data on biological survival, stratified for discontinuation reasons, and predictors that influence survival time have not been explored extensively. Therefore, we aim to explore…Abstract Number: 0860 • ACR Convergence 2020
PREVAIL 1: A Multiple Ascending Dose Study in Normal Healthy Volunteers of PRV-3279, a Novel Bispecific DART Molecule Targeting CD32B and CD79B on B Cells, with Potential for Treatment of SLE
Background/Purpose: B-cell targeted therapeutics have proven efficacious in the treatment of autoimmune disorders. A desired improvement in efficacy and safety necessitate the development of alternate,…Abstract Number: 0986 • ACR Convergence 2020
BIIB059, a Humanized Monoclonal Antibody Targeting Blood Dendritic Cell Antigen 2 on Plasmacytoid Dendritic Cells, Shows Dose-Related Efficacy in a Phase 2 Study in Participants with Active Cutaneous Lupus Erythematosus
Background/Purpose: No approved targeted therapies have been developed for cutaneous lupus erythematosus (CLE), a disfiguring autoimmune disease that severely impairs quality of life.1 BIIB059 is…Abstract Number: 1342 • ACR Convergence 2020
Efficacy Outcomes Following Etanercept Withdrawal by Sustained Remission Status in Patients with Nr-axSpA: Results from RE-EMBARK
Background/Purpose: Etanercept (ETN) is effective and well tolerated in patients with non-radiographic axial spondyloarthritis (nr-axSpA). However, there is limited information on the effects of withdrawing…Abstract Number: 1465 • ACR Convergence 2020
The Impact of the Combined Vaccination Scheme Against Streptococcus Pneumoniae on the Incidence of Related Infections in Patients with Rheumatoid Arthritis Treated with Biologic or Targeted Synthetic DMARD: Data from BIOBADASER 3.0
Background/Purpose: Respiratory infections are among the leading causes of hospitalization in rheumatoid arthritis (RA) and Streptococcus Pneumoniae (SP) is one of the most frequent pathogens…Abstract Number: 1840 • ACR Convergence 2020
A Novel Biomarker Identifies Systemic Lupus Erythematous (SLE) Patients Who Benefit from Obexelimab (XmAb®5871) Treatment
Background/Purpose: We previously reported Phase 2 SLE trial results for obexelimab, a CD19-targeted FcγRIIb engager that suppresses B-cell activation [1]. The primary endpoint, which measured…Abstract Number: 0124 • ACR Convergence 2020
Appropriate Timing of Denosumab Dosing and Subsequent Therapy After Discontinuation: An Academic Medical Center Experience
Background/Purpose: Denosumab, a monoclonal antibody that binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) is a popular choice for osteoporosis therapy. However,…Abstract Number: 0236 • ACR Convergence 2020
Safety and Usability of Infliximab Administration by Auto-injector (AI) and Pre-filled Syringe (PFS) in Patients with Active Rheumatoid Arthritis (RA): Patient-reported Experience from a Multicenter, Randomized Controlled Pivotal Trial
Background/Purpose: The subcutaneous (SC) formulation of CT-P13 received marketing authorization for RA from the EMA by demonstrating non-inferiority compared to CT-P13 intravenous for efficacy in…Abstract Number: 0365 • ACR Convergence 2020
Experience with Apremilast in Treatment of Psoriatic Arthritis in US Clinical Practice; Assessments from Trio Health and the American Rheumatology Network (ARN)
Background/Purpose: Apremilast is the one targeted immune modulating (TIM) treatment for psoriatic arthritis (PsA) that may be combined with csDMARDs, biologic therapies, or used as…Abstract Number: 0579 • ACR Convergence 2020
Risk Factors of Nonadherence in New Rheumatoid Arthritis Patients
Background/Purpose: Biologic disease-modifying antirheumatic drug (bDMARD) therapies are commonly prescribed for rheumatoid arthritis (RA) treatment. However, their high out-of-pocket (OOP) cost may limit patient access…Abstract Number: 0805 • ACR Convergence 2020
The PROPER Study: Results of the First Interim Analysis of a Pan-EU Real-World Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
Background/Purpose: SB5, an adalimumab biosimilar received EU marketing authorisation in August 2017, based on the totality of evidence from pre-clinical and clinical Phase I and…Abstract Number: 0880 • ACR Convergence 2020
Ixekizumab Improves Signs and Symptoms of Patients with Radiographic and Non-radiographic Axial Spondyloarthritis and Extra-articular Manifestation of Enthesitis Through 16 Weeks
Background/Purpose: Axial SpA (axSpA) is a chronic inflammatory disease affecting the spine and sacroiliac (SI) joints and has two subtypes that represent the spectrum of…Abstract Number: 1009 • ACR Convergence 2020
Missing Data and Multiple Imputation in Rheumatoid Arthritis Registries Using Sequential Random Forest Method
Background/Purpose: Missing data in clinical epidemiological researches violate the intention to treat principle, reduce statistical power and can induce bias if they are related to…Abstract Number: 1347 • ACR Convergence 2020
Predictors of Response in Patients with Non-Radiographic Axial Spondyloarthritis Receiving Certolizumab Pegol in the C-axSpAnd Study
Background/Purpose: Identification of predictive clinical factors of long-term treatment response in non-radiographic axial spondyloarthritis (nr-axSpA) may contribute to improved management of patients with this chronic…
ACR Meeting Abstracts